nach oben

Cancer and Metastasis Reviews

Erschienen in:

31.01.2023

KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?

verfasst von: Sitaram Harihar, Danny R. Welch

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Present therapeutic approaches do not effectively target metastatic cancers, often limited by their inability to eliminate already-seeded non-proliferative, growth-arrested, or therapy-resistant tumor cells. Devising effective approaches targeting dormant tumor cells has been a focus of cancer clinicians for decades. However, progress has been limited due to limited understanding of the tumor dormancy process. Studies on tumor dormancy have picked up pace and have resulted in the identification of several regulators. This review focuses on KISS1, a metastasis suppressor gene that suppresses metastasis by keeping tumor cells in a state of dormancy at ectopic sites. The review explores mechanistic insights of KISS1 and discusses its potential application as a therapeutic against metastatic cancers by eliminating quiescent cells or inducing long-term dormancy in tumor cells.

Welch, D. R., & Hurst, D. R. (2019). Defining the hallmarks of metastasis. Cancer Research, 79(12), 3011–3027. https://doi.org/10.1158/0008-5472.CAN-19-0458CrossRefPubMedPubMedCentral

Fidler, I. J. (1970). Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125l–5-lodo-2’-deoxyuridine. Journal of the National Cancer Institute, 45(4), 773–782. https://doi.org/10.1093/jnci/45.4.773CrossRefPubMed

Moore, N., & Lyle, S. (2011). Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. Journal of Oncology, 2011, 1–11. https://doi.org/10.1155/2011/396076CrossRef

Recasens, A., & Munoz, L. (2019). Targeting cancer cell dormancy. Trends in Pharmacological Sciences, 40(2), 128–141. https://doi.org/10.1016/j.tips.2018.12.004CrossRefPubMed

Tang, D. G. (2012). Understanding cancer stem cell heterogeneity and plasticity. Cell Research, 22(3), 457–472. https://doi.org/10.1038/cr.2012.13CrossRefPubMedPubMedCentral

Phan, T. G., & Croucher, P. I. (2020). The dormant cancer cell life cycle. Nature Reviews Cancer, 20(7), 398–411. https://doi.org/10.1038/s41568-020-0263-0CrossRefPubMed

Davis, J. E. J., Kirk, J., Ji, Y., & Tang, D. G. (2019). Tumor dormancy and slow-cycling cancer cells. Advances in Experimental Medicine and Biology, 1164, 199–206. https://doi.org/10.1007/978-3-030-22254-3_15CrossRefPubMedPubMedCentral

Bragado, P., Sosa, M. S., Keely, P., Condeelis, J., & Aguirre-Ghiso, J. A. (2012). Microenvironments dictating tumor cell dormancy. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 195, 25–39. https://doi.org/10.1007/978-3-642-28160-0_3CrossRefPubMed

Gomis, R. R., & Gawrzak, S. (2017). Tumor cell dormancy. Molecular oncology, 11(1), 62–78. https://doi.org/10.1016/j.molonc.2016.09.009CrossRefPubMedPubMedCentral

10.

Hedley, B. D., Winquist, E., & Chambers, A. F. (2004). Therapeutic targets for antimetastatic therapy. Expert opinion on therapeutic targets, 8(6), 527–536. https://doi.org/10.1517/14728222.8.6.527CrossRefPubMed

11.

Goss, P. E., & Chambers, A. F. (2010). Does tumour dormancy offer a therapeutic target? Nature reviews. Cancer, 10(12), 871–877. https://doi.org/10.1038/nrc2933CrossRefPubMed

12.

Neophytou, C. M., Kyriakou, T.-C., & Papageorgis, P. (2019). Mechanisms of metastatic tumor dormancy and implications for cancer therapy. International journal of molecular sciences, 20(24). https://doi.org/10.3390/ijms20246158

13.

Saleh, T., Bloukh, S., Carpenter, V. J., Alwohoush, E., Bakeer, J., Darwish, S., … Gewirtz, D. A. (2020). Therapy-induced senescence: An “old” friend becomes the enemy. Cancers, 12(4). https://doi.org/10.3390/cancers12040822

14.

Neophytou, C., Boutsikos, P., & Papageorgis, P. (2018). Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Frontiers in oncology, 8, 31. https://doi.org/10.3389/fonc.2018.00031CrossRefPubMedPubMedCentral

15.

Iiizumi, M., Liu, W., Pai, S. K., Furuta, E., & Watabe, K. (2008). Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy. Biochimica et biophysica acta, 1786(2), 87–104. https://doi.org/10.1016/j.bbcan.2008.07.002CrossRefPubMedPubMedCentral

16.

Hurst, D. R., & Welch, D. R. (2011). Metastasis suppressor genes. At the interface between the environment and tumor cell growth. International Review of Cell and Molecular Biology, 286, 107–180. https://doi.org/10.1016/B978-0-12-385859-7.00003-3CrossRefPubMedPubMedCentral

17.

Steeg, P. S., Ouatas, T., Halverson, D., Palmieri, D., & Salerno, M. (2003). Metastasis suppressor genes: Basic biology and potential clinical use. Clinical breast cancer, 4(1), 51–62. https://doi.org/10.3816/cbc.2003.n.012CrossRefPubMed

18.

Smith, S. C., & Theodorescu, D. (2009). Learning therapeutic lessons from metastasis suppressor proteins. Nature Reviews Cancer, 9, 253–264. https://doi.org/10.1038/nrc2594CrossRefPubMedPubMedCentral

19.

Park, K. C., Paluncic, J., Kovacevic, Z., & Richardson, D. R. (2020). Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer. Free Radical Biology and Medicine, 157, 154–175. https://doi.org/10.1016/j.freeradbiomed.2019.05.020CrossRefPubMed

20.

Kauffman, E. C., Robinson, V. L., Stadler, W. M., Sokoloff, M. H., & Rinker-Schaeffer, C. W. (2003). Metastasis suppression: The evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. Journal of Urology, 169(3), 1122–1133. https://doi.org/10.1097/01.ju.0000051580.89109.4bCrossRefPubMed

21.

Bohl, C. R., Harihar, S., Denning, W. L., Sharma, R., & Welch, D. R. (2014). Metastasis suppressors in breast cancers: Mechanistic insights and clinical potential. Journal of Molecular Medicine, 92(1), 13–30. https://doi.org/10.1007/s00109-013-1109-yCrossRefPubMed

22.

Beck, B. H., & Welch, D. R. (2010). The KISS1 metastasis suppressor: A good night kiss for disseminated cancer cells. European Journal of Cancer, 46(7), 1283–1289. https://doi.org/10.1016/j.ejca.2010.02.023CrossRefPubMedPubMedCentral

23.

Chen, X., Xu, Z., & Wang, Y. (2011). Recent advances in breast cancer metastasis suppressor 1. The International journal of biological markers, 26(1), 1–8. https://doi.org/10.5301/jbm.2011.6267CrossRefPubMed

24.

Hedley, B. D., & Chambers, A. F. (2009). Tumor dormancy and metastasis. Advances in cancer research, 102, 67–101. https://doi.org/10.1016/S0065-230X(09)02003-XCrossRefPubMed

25.

Osisami, M., & Keller, E. T. (2013). Mechanisms of metastatic tumor dormancy. Journal of clinical medicine, 2(3), 136–150. https://doi.org/10.3390/jcm2030136CrossRefPubMedPubMedCentral

26.

Horak, C. E., Lee, J. H., Marshall, J. C., Shreeve, S. M., & Steeg, P. S. (2008). The role of metastasis suppressor genes in metastatic dormancy. APMIS, 116(7–8), 586–601. https://doi.org/10.1111/j.1600-0463.2008.01027.xCrossRefPubMedPubMedCentral

27.

Harihar, S., Ray, S., Narayanan, S., Santhoshkumar, A., Ly, T., & Welch, D. R. (2020). Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1. Clinical and Experimental Metastasis, 37(2). https://doi.org/10.1007/s10585-020-10030-6

28.

Ly, T., Harihar, S., & Welch, D. R. (2020). KISS1 in metastatic cancer research and treatment: Potential and paradoxes. Cancer and Metastasis Reviews, 39, 739–754. https://doi.org/10.1007/s10555-020-09868-9CrossRefPubMed

29.

Crist, S. B., & Ghajar, C. M. (2021). When a house is not a home: A survey of antimetastatic niches and potential mechanisms of disseminated tumor cell suppression. Annual Review of Pathology: Mechanisms of Disease, 16, 409–432. https://doi.org/10.1146/annurev-pathmechdis-012419-032647CrossRef

30.

Kang, Y., & Pantel, K. (2013). Tumor cell dissemination: Emerging biological insights from animal models and cancer patients. Cancer Cell, 23(5), 573–581. https://doi.org/10.1016/j.ccr.2013.04.017CrossRefPubMedPubMedCentral

31.

Wikman, H., Vessella, R., & Pantel, K. (2008). Cancer micrometastasis and tumour dormancy. APMIS : Acta pathologica, microbiologica, et immunologica Scandinavica, 116(7–8), 754–770. https://doi.org/10.1111/j.1600-0463.2008.01033.xCrossRefPubMed

32.

Izraely, S., & Witz, I. P. (2021). Site-specific metastasis: A cooperation between cancer cells and the metastatic microenvironment. International journal of cancer, 148(6), 1308–1322. https://doi.org/10.1002/ijc.33247CrossRefPubMed

33.

Grzelak, C. A., & Ghajar, C. M. (2017). Metastasis “systems” biology: How are macro-environmental signals transmitted into microenvironmental cues for disseminated tumor cells? Current opinion in cell biology, 48, 79–86. https://doi.org/10.1016/j.ceb.2017.06.002CrossRefPubMed

34.

Mirzayans, R., Andrais, B., & Murray, D. (2018). Roles of polyploid/multinucleated giant cancer cells in metastasis and disease relapse following anticancer treatment. Cancers, 10(4). https://doi.org/10.3390/cancers10040118

35.

Sceneay, J., Smyth, M. J., & Möller, A. (2013). The pre-metastatic niche: Finding common ground. Cancer metastasis reviews, 32(3–4), 449–464. https://doi.org/10.1007/s10555-013-9420-1CrossRefPubMed

36.

Liu, Y., & Cao, X. (2016). Characteristics and significance of the pre-metastatic niche. Cancer Cell, 30(5), 668–681. https://doi.org/10.1016/j.ccell.2016.09.011CrossRefPubMed

37.

Aguirre-Ghiso, J. A., & Sosa, M. S. (2018). Emerging topics on disseminated cancer cell dormancy and the paradigm of metastasis. Annual Review of Cancer Biology, 2, 377–393. https://doi.org/10.1146/annurev-cancerbio-030617-050446CrossRef

38.

Araos, J., Sleeman, J. P., & Garvalov, B. K. (2018). The role of hypoxic signalling in metastasis: Towards translating knowledge of basic biology into novel anti-tumour strategies. Clinical & experimental metastasis, 35(7), 563–599. https://doi.org/10.1007/s10585-018-9930-xCrossRef

39.

Butturini, E., Carcereri de Prati, A., Boriero, D., & Mariotto, S. (2019). Tumor dormancy and interplay with hypoxic tumor microenvironment. International journal of molecular sciences, 20(17). https://doi.org/10.3390/ijms20174305

40.

Walker, N. D., Patel, J., Munoz, J. L., Hu, M., Guiro, K., Sinha, G., & Rameshwar, P. (2016). The bone marrow niche in support of breast cancer dormancy. Cancer letters, 380(1), 263–271. https://doi.org/10.1016/j.canlet.2015.10.033CrossRefPubMed

41.

Attaran, S., & Bissell, M. J. (2022). The role of tumor microenvironment and exosomes in dormancy and relapse. Seminars in cancer biology, 78, 35–44. https://doi.org/10.1016/j.semcancer.2021.09.008CrossRefPubMed

42.

Hernández-Barranco, A., Nogués, L., & Peinado, H. (2021). Could extracellular vesicles contribute to generation or awakening of “sleepy” metastatic niches? Frontiers in cell and developmental biology, 9, 625221. https://doi.org/10.3389/fcell.2021.625221CrossRefPubMedPubMedCentral

43.

Patel, S. A., Meyer, J. R., Greco, S. J., Corcoran, K. E., Bryan, M., & Rameshwar, P. (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-β. The Journal of Immunology, 184(10), 5885–5894. https://doi.org/10.4049/jimmunol.0903143CrossRefPubMed

44.

Roodman, G. D. (2004). Mechanisms of bone metastasis. New England Journal of Medicine, 350(16), 1655–1664. https://doi.org/10.1056/nejmra030831CrossRefPubMed

45.

Psaila, B., & Lyden, D. (2009). The metastatic niche: Adapting the foreign soil. Nature Reviews Cancer, 9, 285–293. https://doi.org/10.1038/nrc2621CrossRefPubMedPubMedCentral

46.

Dianat-Moghadam, H., Azizi, M., Eslami-S, Z., Cortés-Hernández, L. E., Heidarifard, M., Nouri, M., & Alix-Panabières, C. (2020). The role of circulating tumor cells in the metastatic cascade: Biology, technical challenges, and clinical relevance. Cancers, 12(4). https://doi.org/10.3390/cancers12040867

47.

Joosse, S. A., Gorges, T. M., & Pantel, K. (2015). Biology, detection, and clinical implications of circulating tumor cells. EMBO molecular medicine, 7(1), 1–11. https://doi.org/10.15252/emmm.201303698CrossRefPubMed

48.

Ramamoorthi, G., Kodumudi, K., Gallen, C., Zachariah, N. N., Basu, A., Albert, G., … Czerniecki, B. J. (2022). Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Seminars in cancer biology, 78, 78–89. https://doi.org/10.1016/j.semcancer.2021.02.004

49.

Esposito, M., & Kang, Y. (2014). Targeting tumor-stromal interactions in bone metastasis. Pharmacology & therapeutics, 141(2), 222–233. https://doi.org/10.1016/j.pharmthera.2013.10.006CrossRef

50.

Aguado, B. A., Bushnell, G. G., Rao, S. S., Jeruss, J. S., & Shea, L. D. (2017). Engineering the pre-metastatic niche. Nature Biomedical Engineering, 1(0077). https://doi.org/10.1038/s41551-017-0077

51.

Lim, A. R., & Ghajar, C. M. (2022). Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse. Seminars in cancer biology, 78, 104–123. https://doi.org/10.1016/j.semcancer.2021.05.007CrossRefPubMed

52.

Kamińska, K., Szczylik, C., & Bielecka, Z. F. (2015). The role of the cell-cell interactions in cancer progression. Journal of Cellular and Molecular Medicine, 19(2), 283–296. https://doi.org/10.1111/jcmm.12408CrossRefPubMedPubMedCentral

53.

De Wever, O., Van Bockstal, M., Mareel, M., Hendrix, A., & Bracke, M. (2014). Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Seminars in cancer biology, 25, 33–46. https://doi.org/10.1016/j.semcancer.2013.12.009CrossRefPubMed

54.

Kwa, M. Q., Herum, K. M., & Brakebusch, C. (2019). Cancer-associated fibroblasts: How do they contribute to metastasis? Clinical and Experimental Metastasis, 36, 71–86. https://doi.org/10.1007/s10585-019-09959-0CrossRefPubMed

55.

Raz, Y., Cohen, N., Shani, O., Bell, R. E., Novitskiy, S. V., Abramovitz, L., … Erez, N. (2018). Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. Journal of Experimental Medicine, 215(12), 3075–3093. https://doi.org/10.1084/jem.20180818

56.

Yeo, S. Y., Lee, K. W., Shin, D., An, S., Cho, K. H., & Kim, S. H. (2018). A positive feedback loop bi-stably activates fibroblasts. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-05274-6

57.

Psaila, B., Kaplan, R. N., Port, E. R., & Lyden, D. (2006). Priming the “soil” for breast cancer metastasis: The pre-metastatic niche. Breast disease, 26, 65–74. https://doi.org/10.3233/bd-2007-26106CrossRefPubMed

58.

Ping, Y. F., Yao, X. H., Jiang, J. Y., Zhao, L. T., Yu, S. C., Jiang, T., … Bian, X. W. (n.d.). The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. The Journal of pathology, 224(3), 344–354. https://doi.org/10.1002/path.2908

59.

Potente, M., & Carmeliet, P. (2017). The link between angiogenesis and endothelial metabolism. Annual Review of Physiology. Annual Reviews Inc. https://doi.org/10.1146/annurev-physiol-021115-105134

60.

Wilde, L., Roche, M., Domingo-Vidal, M., Tanson, K., Philp, N., Curry, J., & Martinez-Outschoorn, U. (2017). Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development. Seminars in Oncology, 44(3), 198–203. https://doi.org/10.1053/j.seminoncol.2017.10.004CrossRefPubMedPubMedCentral

61.

Bott, A. J., Maimouni, S., & Zong, W. X. (2019). The pleiotropic effects of glutamine metabolism in cancer. Cancers, 11(6). https://doi.org/10.3390/cancers11060770

62.

Yan, S., Vandewalle, N., De Beule, N., Faict, S., Maes, K., De Bruyne, E., … De Veirman, K. (2019). AXL receptor tyrosine kinase as a therapeutic target in hematological malignancies: Focus on multiple myeloma. Cancers, 11(11). https://doi.org/10.3390/cancers11111727

63.

Yumoto, K., Eber, M. R., & Wang, J. (2016). Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep, 6(36520). https://doi.org/10.1038/srep36520

64.

Prunier, C., Baker, D., ten Dijke, P., & Ritsma, L. (2019). TGF-β family signaling pathways in cellular dormancy. Trends in cancer, 5(1), 66–78. https://doi.org/10.1016/J.TRECAN.2018.10.010CrossRefPubMed

65.

Buijs, J. T., Henriquez, N. V., van Overveld, P. G. M., van der Horst, G., ten Dijke, P., & van der Pluijm, G. (2007). TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clinical & experimental metastasis, 24(8), 609–617. https://doi.org/10.1007/s10585-007-9118-2CrossRef

66.

Bragado, P., Estrada, Y., & Parikh, F. (2013). TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nature Cell Biology, 15(11), 1351–1361. https://doi.org/10.1038/ncb2861CrossRefPubMedPubMedCentral

67.

Kovacevic, Z., Chikhani, S., Lui, G. Y. L., Sivagurunathan, S., & Richardson, D. R. (2013). The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and ras signaling pathways. Antioxidants and Redox Signaling, 18(8), 874–887. https://doi.org/10.1089/ars.2011.4273CrossRefPubMed

68.

Sun, J., Zhang, D., Bae, D. H., Sahni, S., Jansson, P., Zheng, Y., … Richardson, D. R. (2013). Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 34, 1943–1954. https://doi.org/10.1093/carcin/bgt163

69.

Patel, S., Alam, A., Pant, R., & Chattopadhyay, S. (2019). Wnt signaling and its significance within the tumor microenvironment: Novel therapeutic insights. Front Immunol, 10(2872). https://doi.org/10.3389/fimmu.2019.02872

70.

Carreira-Barbosa, F., & Nunes, S. C. (2020). Wnt signaling: Paths for cancer progression. Advances in experimental medicine and biology, 1219, 189–202. https://doi.org/10.1007/978-3-030-34025-4_10CrossRefPubMed

71.

Ranganathan, A. C., Adam, A. P., Zhang, L., & Aguirre-Ghiso, J. A. (2006). Tumor cell dormancy induced by p38SAPK and ER-stress signaling: An adaptive advantage for metastatic cells? Cancer biology & therapy, 5(7), 729–735. https://doi.org/10.4161/cbt.5.7.2968CrossRef

72.

Roux, P. P., & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68(2), 320–344. https://doi.org/10.1128/MMBR.68.2.320-344.2004CrossRefPubMedPubMedCentral

73.

Jahanban-Esfahlan, R., Seidi, K., Manjili, M. H., Jahanban-Esfahlan, A., Javaheri, T., & Zare, P. (2019). Tumor cell dormancy: Threat or opportunity in the fight against cancer. Cancers, 11(8), 1207. https://doi.org/10.3390/cancers11081207CrossRefPubMedPubMedCentral

74.

Kudaravalli, S., den Hollander, P., & Mani, S. A. (2022). Role of p38 MAP kinase in cancer stem cells and metastasis. Oncogene, 41(23), 3177–3185. https://doi.org/10.1038/s41388-022-02329-3CrossRefPubMedPubMedCentral

75.

Sosa, M. S., Parikh, F., & Maia, A. G. (2015). NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nature Communications, 6(1). https://doi.org/10.1038/ncomms7170

76.

Goddard, E. T., Bozic, I., Riddell, S. R., & Ghajar, C. M. (2018). Dormant tumour cells, their niches and the influence of immunity. Nature cell biology, 20(11), 1240–1249. https://doi.org/10.1038/s41556-018-0214-0CrossRefPubMed

77.

Massagué, J., & Ganesh, K. (2021). Metastasis-initiating cells and ecosystems. Cancer discovery, 11(4), 971–994. https://doi.org/10.1158/2159-8290.CD-21-0010CrossRefPubMedPubMedCentral

78.

Wang, H.-F., Wang, S.-S., Huang, M.-C., Liang, X.-H., Tang, Y.-J., & Tang, Y.-L. (2019). Targeting immune-mediated dormancy: A promising treatment of cancer. Frontiers in oncology, 9, 498. https://doi.org/10.3389/fonc.2019.00498CrossRefPubMedPubMedCentral

79.

Lopes, N., & Vivier, E. (2021). Natural killer cells lull tumors into dormancy. Nature, 594(7864), 501–502. https://doi.org/10.1038/d41586-021-01381-5CrossRefPubMed

80.

Steel, J. C., Waldmann, T. A., & Morris, J. C. (2012). Interleukin-15 biology and its therapeutic implications in cancer. Trends in Pharmacological Sciences, 33(1), 35–41. https://doi.org/10.1016/j.tips.2011.09.004CrossRefPubMed

81.

Barra, N. G., Chew, M. v, Reid, S., & Ashkar, A. A. (2012). Interleukin-15 treatment induces weight loss independent of lymphocytes. PLoS One, 7(6). https://doi.org/10.1371/journal.pone.0039553

82.

Shi Y Riese DJ 2nd, S. J. (2020). The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Frontiers Pharmacology, 11(574667). https://doi.org/10.3389/fphar.2020.574667

83.

Farrar, J. D., Katz, K. H., Windsor, J., Thrush, G., Scheuermann, R. H., Uhr, J. W., & Street, N. E. (1999). Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. Journal of immunology, 162(5), 2842–2849.CrossRef

84.

Mayhew, V., Omokehinde, T., & Johnson, R. W. (2020). Tumor dormancy in bone. Cancer reports (Hoboken, N.J.), 3(1), e1156. https://doi.org/10.1002/cnr2.1156CrossRefPubMed

85.

Lan, Q., Peyvandi, S., & Duffey, N. (2019). Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene, 38(15), 2814–2829. https://doi.org/10.1038/s41388-018-0624-2CrossRefPubMed

86.

Bidwell, B. N., Slaney, C. Y., & Withana, N. P. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 18(8), 1224–1231. https://doi.org/10.1038/nm.2830CrossRefPubMed

87.

Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018). CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences, 75(4), 689–713. https://doi.org/10.1007/s00018-017-2686-7CrossRefPubMed

88.

Flies, D. B., Sandler, B. J., Sznol, M., & Chen, L. (2011). Blockade of the B7–H1/PD-1 pathway for cancer immunotherapy. The Yale Journal of Biology and Medicine, 84(4), 409–421.PubMedPubMedCentral

89.

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012). Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology, 24(2), 207–212. https://doi.org/10.1016/j.coi.2011.12.009CrossRefPubMedPubMedCentral

90.

Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020). Roles of IFN-γ in tumor progression and regression: A review. Biomark Research, 8(1). https://doi.org/10.1186/s40364-020-00228-x

91.

Burke, J. D., & Young, H. A. (2019). IFN-γ: A cytokine at the right time, is in the right place. Seminars Immunology, 43(101280). https://doi.org/10.1016/j.smim.2019.05.002

92.

Albrengues, J., Shields, M. A., Ng, D., Park, C. G., Ambrico, A., Poindexter, M. E., … Egeblad, M. (2018). Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science, 361(6409). https://doi.org/10.1126/science.aao4227

93.

Tohme, S., Yazdani, H. O., Al-Khafaji, A. B., Chidi, A. P., Loughran, P., Mowen, K., … Tsung, A. (2016). Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Research, 76(6), 1367–1380. https://doi.org/10.1158/0008-5472.CAN-15-1591

94.

Khan, I., & Steeg, P. S. (2018). Metastasis suppressors: Functional pathways. Laboratory Investigation, 98, 198–210. https://doi.org/10.1038/labinvest.2017.104CrossRefPubMed

95.

Stafford, L. J., Vaidya, K. S., & Welch, D. R. (2008). Metastasis suppressors genes in cancer. International Journal of Biochemistry and Cell Biology, 40(5), 874–891. https://doi.org/10.1016/j.biocel.2007.12.016CrossRefPubMed

96.

Nash, K. T., Phadke, P. A., Navenot, J. M., Hurst, D. R., Accavitti-Loper, M. A., Sztul, E., … Welch, D. R. (2007). Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy [published correction appears in J Natl Cancer Inst. Journal of National Cancer Institute, 99(4), 309–321. https://doi.org/10.1093/jnci/djk053

97.

Steeg, P. S., Bevilacqua, G., Pozzatti, R., Liotta, L. A., & Sobel, M. E. (1988). Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Research, 48(22), 6550–6554.PubMed

98.

Welch, D. R., Chen, P., Miele, M. E., McGary, C. T., Bower, J. M., Stanbridge, E. J., & Weissman, B. E. (1994). Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene, 9(1), 255–262.PubMed

99.

Goldberg, S. F., Miele, M. E., Hatta, N., Takata, M., Paquette-Straub, C., Freedman, L. P., & Welch, D. R. (2003). Melanoma metastasis suppression by chromosome 6: Evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Research, 63(2), 432–440.PubMed

100.

Cebrian, V., Fierro, M., Orenes-Piero, E., Grau, L., Moya, P., Ecke, T., … Sánchez-Carbayo, M. (2011). KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. American Journal of Pathology, 179(2), 540–546. https://doi.org/10.1016/j.ajpath.2011.05.009

101.

Lee, J. H., & Welch, D. R. (1997). Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Research, 57(12), 2384–2387.PubMed

102.

Cvetković, D., Babwah, A. V., & Bhattacharya, M. (2013). Kisspeptin/KISSIR system in breast cancer. Journal of Cancer, 4(8), 653–661. https://doi.org/10.7150/jca.7626CrossRefPubMedPubMedCentral

103.

McNally, L. R., Welch, D. R., Beck, B. H., Stafford, L. J., Long, J. W., Sellers, J. C., … Buchsbaum, D. J. (2010). KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clinical and Experimental Metastasis, 27(8), 591–600. https://doi.org/10.1007/s10585-010-9349-5

104.

Jiang, Y., Berk, M., Singh, L. S., Tan, H., Yin, L., Powell, C. T., & Xu, Y. (2005). KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clinical and Experimental Metastasis, 22(5), 369–376. https://doi.org/10.1007/s10585-005-8186-4CrossRefPubMed

105.

Okugawa, Y., Inoue, Y., Tanaka, K., Toiyama, Y., Shimura, T., Okigami, M., … M., K. (2013). Loss of the metastasis suppressor gene KiSS1 is associated with lymph node metastasis and poor prognosis in human colorectal cancer. Oncology Reports, 30(3), 1449–1454. https://doi.org/10.3892/or.2013.2558

106.

Kostakis, I. D., Agrogiannis, G., Vaiopoulos, A. G., Mylona, E., Patsouris, E., Kouraklis, G., & Koutsilieris, M. (2015). A clinicopathological analysis of KISS1 and KISS1R expression in colorectal cancer. APMIS, 123(7), 629–637. https://doi.org/10.1111/apm.12397CrossRefPubMed

107.

Kostakis, I. D., Agrogiannis, G., Vaiopoulos, A. G., Mylona, E., Patsouris, E., Kouraklis, G., & Koutsilieris, M. (2018). KISS1 and KISS1R expression in gastric cancer. Journal of B.U.O.N, 23(3), 598–603.

108.

Lee, J. H., Miele, M. E., Hicks, D. J., Phillips, K. K., Trent, J. M., Weissman, B. E., & Welch, D. R. (1996). KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. Journal of the National Cancer Institute, 88(23), 1731–1737. https://doi.org/10.1093/jnci/88.23.1731CrossRefPubMed

109.

Zhang, Y., Tang, Y. J., Li, Z. H., Pan, F., Huang, K., & Xu, G. H. (2013). KiSS1 inhibits growth and invasion of osteosarcoma cells through inhibition of the MAPK pathway. European Journal of Histochemistry, 57(4), 200–205. https://doi.org/10.4081/ejh.2013.e30CrossRef

110.

Zheng, S., Chang, Y., Hodges, K. B., Sun, Y., Ma, X., Xueyi, … Cheng, L. (2010). Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival.Anticancer Research, 30(3), 713–718.

111.

Sun, Y. B., & Xu, S. (2013). Expression of KISS1 and KISS1R (GPR54) may be used as favorable prognostic markers for patients with non-small cell lung cancer. International Journal of Oncology, 43(2), 521–530. https://doi.org/10.3892/ijo.2013.1967CrossRefPubMed

112.

Schmidt, E., Haase, M., Ziegler, E., Emons, G., & Gründker, C. (2014). Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells. International Journal of Gynecological Cancer, 24(2), 210–217. https://doi.org/10.1097/IGC.0000000000000050CrossRefPubMed

113.

Martins, C. M. O., Fernandes, B. F., Antecka, E., Di Cesare, S., Mansure, J. J. C., Marshall, J. C., & Burnier, M. N. (2008). Expression of the metastasis suppressor gene KISS1 in uveal melanoma. Eye, 22(5), 707–711. https://doi.org/10.1038/sj.eye.6703090CrossRefPubMed

114.

Jiffar, T., Yilmaz, T., Lee, J., Hanna, E., El-Naggar, A., Yu, D., … Kupferman, M. E. (2011). KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene, 30(28), 3163–3173. https://doi.org/10.1038/onc.2011.39

115.

Chen, Y., Zhang, C., Chen, J., Zhang, B., Zhang, H., Yang, X., … Wu, Q. (2018). Expression of transcription factor 21 (TCF21) and upregulation its level inhibits invasion and metastasis in esophageal squamous cell carcinoma. Medical Science Monitor, 24, 4128–4136. https://doi.org/10.12659/msm.909138

116.

Ikeguchi, M., Hirooka, Y., & Kaibara, N. (2003). Quantitative reverse transcriptase polymerase chain reaction analysis for KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 129, 531–535. https://doi.org/10.1007/s00432-003-0469-zCrossRefPubMed

117.

Zang, S., Liu, J. F., Wang, B., Gao, L., & Huang, A. (2009). Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. Anatomical Record, 292(8), 1128–1134. https://doi.org/10.1002/ar.20950CrossRef

118.

Goertzen, C. G., Dragan, M., Turley, E., Babwah, A. V., & Bhattacharya, M. (2016). KISS1R signaling promotes invadopodia formation in human breast cancer cell via β-arrestin2/ERK. Cellular Signalling, 28(3), 165–176. https://doi.org/10.1016/j.cellsig.2015.12.010CrossRefPubMed

119.

Tian, J., Al-Odaini, A. A., Wang, Y., Korah, J., Dai, M., Xiao, L., … Lebrun, J. J. (2018). KiSS1 gene as a novel mediator of TGFβ-mediated cell invasion in triple negative breast cancer. Cellular Signalling, 42, 1–10. https://doi.org/10.1016/j.cellsig.2017.10.002

120.

Kim, C.-W., Lee, H. K., Nam, M.-W., Lee, G., & Choi, K.-C. (2022). The role of KiSS1 gene on the growth and migration of prostate cancer and the underlying molecular mechanisms. Life sciences, 310, 121009. https://doi.org/10.1016/j.lfs.2022.121009CrossRefPubMed

121.

Marot, D., Bieche, I., Aumas, C., Esselin, S., Bouquet, C., Vacher, S., … De Roux, N. (2007). High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. Endocrine-Related Cancer, 14(3), 691–702. https://doi.org/10.1677/ERC-07-0012

122.

Lee, D. K., Nguyen, T., O’Neill, G. P., Cheng, R., Liu, Y., Howard, A. D., … O’Dowd, B. F. (1999). Discovery of a receptor related to the galanin receptors. FEBS Letters, 446(1), 103–107. https://doi.org/10.1016/S0014-5793(99)00009-5

123.

Ohtaki, T., Shintani, Y., Honda, S., Matsumoto, H., Hori, A., Kanehashi, K., … Fujino, M. (2001). Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature, 411(6837), 613–617. https://doi.org/10.1038/35079135

124.

Muir, A. I., Chamberlain, L., Elshourbagy, N. A., Michalovich, D., Moore, D. J., Calamari, A., … Harrison, D. C. (2001). AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. Journal of Biological Chemistry, 276, 28969–28975. https://doi.org/10.1074/jbc.M102743200

125.

Kotani, M., Detheux, M., Vandenbogaerde, A., Communi, D., Vanderwinden, J. M., le Poul, E., … Parmentier, M. (2001). The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry, 276(37), 34631–34636. https://doi.org/10.1074/jbc.M104847200

126.

Seminara, S. B. (2005). Metastin and its G protein-coupled receptor, GPR54: Critical pathway modulating GnRH secretion. Frontiers in neuroendocrinology, 26(3–4), 131–138. https://doi.org/10.1016/j.yfrne.2005.10.001CrossRefPubMed

127.

Nimri, R., Lebenthal, Y., Lazar, L., Chevrier, L., Phillip, M., Bar, M., … Gat-Yablonski, G. (2011). A novel loss-of-function mutation in GPR54/KISS1R leads to hypogonadotropic hypogonadism in a highly consanguineous family. Journal of Clinical Endocrinology Metabolism, 96(3), E536–45. https://doi.org/10.1210/jc.2010-1676

128.

Carel, J.-C., Chaussain, J.-L., Milgrom, E., de Roux, N., Genin, E., Matsuda, F., … Matsuda, F. (2003). Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences, 100(19), 10972–10976. https://doi.org/10.1073/pnas.1834399100

129.

Topalglu, A. K., Tello, J. A., Kotan, L. D., Ozbek, M. N., Yilmaz, M. B., Erdogan, S., … Yuksel, B. (2012). Inactivating KISS1 mutation and hypogonadotropic hypogonadism. Obstetrical {\&} Gynecological Survey, 67(6), 352–353. https://doi.org/10.1097/ogx.0b013e31825bc1be

130.

Hiden, U., Bilban, M., Knöfler, M., & Desoye, G. (2007). Kisspeptins and the placenta: Regulation of trophoblast invasion. Reviews in endocrine & metabolic disorders, 8(1), 31–39. https://doi.org/10.1007/s11154-007-9030-8CrossRef

131.

Padilla, S. L., Perez, J. G., Ben-Hamo, M., Johnson, C. W., Sanchez, R. E. A., Bussi, I. L., … de la Iglesia, H. O. (2019). Kisspeptin neurons in the arcuate nucleus of the hypothalamus orchestrate circadian rhythms and metabolism. Current Biology, 29(4), 592–604. https://doi.org/10.1016/j.cub.2019.01.022

132.

Diamantopoulou, Z., Castro-Giner, F., Schwab, F. D., Foerster, C., Saini, M., Budinjas, S., … Aceto, N. (2022). The metastatic spread of breast cancer accelerates during sleep. Nature, 607(7917), 156–162. https://doi.org/10.1038/s41586-022-04875-y

133.

De Opakua, A. I., Merino, N., Villate, M., Cordeiro, T. N., Ormaza, G., Sánchez-Carbayo, M., … Blanco, F. J. (2017). The metastasis suppressor KISS1 is an intrinsically disordered protein slightly more extended than a random coil. PLoS ONE, 12(2). https://doi.org/10.1371/journal.pone.0172507

134.

Shin, R., Welch, D. R., Mishra, V. K., Nash, K. T., Hurst, D. R., & Rama Krishna, N. (2009). Nuclear magnetic resonance and circular dichroism study of metastin (Kisspeptin-54) structure in solution. Clinical and Experimental Metastasis, 26(6), 527–533. https://doi.org/10.1007/s10585-009-9252-0CrossRefPubMed

135.

Takino, T., Koshikawa, N., Miyamori, H., Tanaka, M., Sasaki, T., Okada, Y., … Sato, H. (2003). Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene, 22(30), 4617–4626. https://doi.org/10.1038/sj.onc.1206542

136.

Milton, N. G. N. (2012). In vitro activities of kissorphin, a novel hexapeptide KiSS-1 derivative, in neuronal cells. Journal of Amino Acids, 2012, 1–6. https://doi.org/10.1155/2012/691463CrossRef

137.

Yeo, R. L., Tsunekawa, K., Mi, J. M., Haet, N. U., Hwang, J. I., Osugi, T., … Tsutsui, K. (2009). Molecular evolution of multiple forms of kisspeptins and GPR54 receptors in vertebrates. Endocrinology, 150(6), 2837–2846. https://doi.org/10.1210/en.2008-1679

138.

Akazome, Y., Kanda, S., Okubo, K., & Oka, Y. (2010). Functional and evolutionary insights into vertebrate kisspeptin systems from studies of fish brain. Journal of Fish Biology, 76(1), 161–182. https://doi.org/10.1111/j.1095-8649.2009.02496.xCrossRefPubMed

139.

Harihar, S., Pounds, K. M., Iwakuma, T., Seidah, N. G., & Welch, D. R. (2014). Furin is the major proprotein convertase required for KISS1-to-Kisspeptin processing. PLoS ONE, 9(1). https://doi.org/10.1371/journal.pone.0084958

140.

Navenot, J.-M., Fujii, N., & Peiper, S. C. (2009). KiSS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis. Molecular Pharmacology, 75(5), 1074–1083. https://doi.org/10.1124/mol.108.054270CrossRefPubMed

141.

Navenot, J.-M., Fujii, N., & Peiper, S. C. (2009). Activation of Rho and Rho-associated kinase by GPR54 and KiSS1 metastasis suppressor gene product induces changes of cell morphology and contributes to apoptosis. Molecular Pharmacology, 75(6), 1300–1306. https://doi.org/10.1124/mol.109.055095CrossRefPubMed

142.

Cho, S. G., Li, D., Stafford, L. J., Luo, J., Rodriguez-Villanueva, M., Wang, Y., & Liu, M. (2009). KiSS1 suppresses TNFα-induced breast cancer cell invasion via an inhibition of RhoA-mediated NF-κB activation. Journal of Cellular Biochemistry, 107(6), 1139–1149. https://doi.org/10.1002/jcb.22216CrossRefPubMedPubMedCentral

143.

Harms, J. F., Welch, D. R., & Miele, M. E. (2003). KISS1 metastasis suppression and emergent pathways. Clinical and Experimental Metastasis, 20, 11–18. https://doi.org/10.1023/A:1022530100931CrossRefPubMed

144.

Teng, Y., Liu, M., & Cowell, J. K. (2011). Functional interrelationship between the WASF3 and KISS1 metastasis-associated genes in breast cancer cells. International Journal of Cancer, 129(12), 2825–2835. https://doi.org/10.1002/ijc.25964CrossRefPubMedPubMedCentral

145.

Arab, K., Smith, L. T., Gast, A., Weichenhan, D., Huang, J. P. H., Claus, R., … Plass, C. (2011). Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. Carcinogenesis, 32(10), 1467–1473. https://doi.org/10.1093/carcin/bgr138

146.

Dotterweich, J., Tower, R. J., Brandl, A., Müller, M., Hofbauer, L. C., Beilhack, A., … Jakob, F. (2016). The KISS1 receptor as an in vivo microenvironment imaging biomarker of multiple myeloma bone disease. PLoS ONE, 11(5). https://doi.org/10.1371/journal.pone.0155087

147.

Lu, X., Mu, E., & Wei, Y. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell, 20(6), 701–714. https://doi.org/10.1016/j.ccr.2011.11.002CrossRefPubMedPubMedCentral

148.

Barkan, D., Kleinman, H., & Simmons, J. L. (2008). Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research, 68(15), 6241–6250. https://doi.org/10.1158/0008-5472.CAN-07-6849CrossRefPubMedPubMedCentral

149.

Akhtar, M., Haider, A., Rashid, S., & Al-Nabet, A. D. M. H. (2019). Paget’s “seed and Soil” theory of cancer metastasis: An idea whose time has come. Advances in Anatomic Pathology, 26(1), 69–74. https://doi.org/10.1097/PAP.0000000000000219CrossRefPubMed

150.

Lee, K. H., & Kim, J. R. (2009). Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer. Oncology Research, 18(2–3), 107–116. https://doi.org/10.3727/096504009789954591CrossRefPubMed

151.

Kaverina, N., Borovjagin, A. V, Kadagidze, Z., Baryshnikov, A., Baryshnikova, M., Malin, D., … Ulasov, I. V. (2017). Astrocytes promote progression of breast cancer metastases to the brain via a KISS1-mediated autophagy. Autophagy, 13(11), 1905–1923. https://doi.org/10.1080/15548627.2017.1360466

152.

Liu, W., Beck, B. H., Vaidya, K. S., Nash, K. T., Feeley, K. P., Ballinger, S. W., … Welch, D. R. (2014). Metastasis suppressor KISS1 Seems to reverse the warburg effect by enhancing mitochondrial biogenesis. Cancer Research, 74(3), 954–963. https://doi.org/10.1158/0008-5472.CAN-13-1183

153.

Tsuruo, T., Iida, H., Makishima, F., Yamori, T., Kawabata, H., Tsukagoshi, S., & Sakurai, Y. (1985). Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil. Cancer Chemotherapy and Pharmacology, 14(1), 30–33. https://doi.org/10.1007/BF00552721CrossRefPubMed

154.

Welch, D. R., Harper, D. E., & Yohem, K. H. (1993). U-77,863: A novel cinnanamide isolated from Streptomyces griseoluteus that inhibits cancer invasion and metastasis. Clinical & experimental metastasis, 11(2), 201–212. https://doi.org/10.1007/BF00114978CrossRef

155.

Peruzzo, R., Costa, R., Bachmann, M., Leanza, L., & Szabò, I. (2020). Mitochondrial metabolism, contact sites and cellular calcium signaling: Implications for tumorigenesis. Cancers, 12(9), 2574. https://doi.org/10.3390/cancers12092574CrossRefPubMedPubMedCentral

156.

McCormack, J. G., & Denton, R. M. (1993). Mitochondrial Ca2+ transport and the role of intramitochondrial Ca2+ in the regulation of energy metabolism. Developmental Neuroscience, 15(3–5), 165–173. https://doi.org/10.1159/000111332CrossRefPubMed

157.

Manley, S. J., Liu, W., & Welch, D. R. (2017). The KISS1 metastasis suppressor appears to reverse the Warburg effect by shifting from glycolysis to mitochondrial beta-oxidation. Journal of Molecular Medicine, 95(9), 951–963. https://doi.org/10.1007/s00109-017-1552-2CrossRefPubMed

158.

Ibrahim-Hashim, A., & Estrella, V. (2019). Acidosis and cancer: From mechanism to neutralization. Cancer and Metastasis Reviews, 38, 149–155. https://doi.org/10.1007/s10555-019-09787-4CrossRefPubMed

159.

Liu, W., Beck, B. H., Vaidya, K. S., Nash, K. T., Feeley, K. P., Ballinger, S. W., … Welch, D. R. (2014). Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. Cancer Research, 74(3), 954–963. https://doi.org/10.1158/0008-5472.CAN-13-1183

160.

Pranzini, E., Raugei, G., & Taddei, M. L. (2022). Metabolic features of tumor dormancy: Possible therapeutic strategies. Cancers, 14(3). https://doi.org/10.3390/cancers14030547

161.

Trevisan, C. M., Montagna, E., De Oliveira, R., Christofolini, D. M., Barbosa, C. P., Crandall, K. A., & Bianco, B. (2018). Kisspeptin/GPR54 system: What do we know about its role in human reproduction? Cellular Physiology and Biochemistry, 49, 1259–1276. https://doi.org/10.1159/000493406CrossRefPubMed

162.

De Tassigny, X. D. A., Jayasena, C., Murphy, K. G., Dhillo, W. S., & Colledge, W. H. (2017). Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. PLoS ONE, 12(5). https://doi.org/10.1371/journal.pone.0176821

163.

Ciaramella, V., Della Corte, C. M., Ciardiello, F., & Morgillo, F. (2018). Kisspeptin and cancer: Molecular interaction, biological functions, and future perspectives. Frontiers in Endocrinology, 9(115). https://doi.org/10.3389/fendo.2018.00115

164.

Werner-Klein, M., & Klein, C. A. (2019). Therapy resistance beyond cellular dormancy. Nature Cell Biology, 21(2), 117–119. https://doi.org/10.1038/s41556-019-0276-7CrossRefPubMed

165.

Sleeman, J., & Steeg, P. S. (2010). Cancer metastasis as a therapeutic target. European journal of cancer (Oxford, England: 1990), 46(7), 1177–1180. https://doi.org/10.1016/j.ejca.2010.02.039CrossRefPubMed

166.

Young, E. D., Strom, K., Tsue, A. F., Usset, J. L., MacPherson, S., McGuire, J. T., & Welch, D. R. (2018). Automated quantitative image analysis for ex vivo metastasis assays reveals differing lung composition requirements for metastasis suppression by KISS1. Clinical and Experimental Metastasis, 35(1–2), 77–86. https://doi.org/10.1007/s10585-018-9882-1CrossRefPubMed

Titel: KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?
verfasst von: Sitaram Harihar
Danny R. Welch
Publikationsdatum: 31.01.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2023
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10090-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?

Dormancy in cancer metastasis: keys to moving forward

Preface

Regulation of dormancy during tumor dissemination: the role of the ECM

Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry

Dormant cancer cells: programmed quiescence, senescence, or both?

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie